CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Double-Blind PlaceboWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)


Name (Synonyms) Correlation
drug1098 Fecal Microbiota Therapy (FMT) Wiki 1.00
drug919 Double-Blind NT-I7 Wiki 1.00
drug2122 Placebo Wiki 0.05

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D003015 Clostridium Infections NIH 1.00

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Double-blind, Randomized, Placebo-controlled, Phase 1, Single-dose, Dose-escalating Trial of Long-acting Recombinant Human IL-7 (NT-I7) for COVID-19

The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): - Safety of a single dose of NT-I7 - The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.

NCT04501796 COVID-19 Drug: Double-Blind NT-I7 Drug: Double-Blind Placebo

Primary Outcomes

Description: Assessment of the number and severity of AEs possibly, probably, or definitely related to study drug evaluated at 7 and 30 days.

Measure: Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion

Time: Up to approximately 30 days

Secondary Outcomes

Description: Assessment of the trajectory of ALC, CD4, CD8, NK, B, and MAIT cells measured at days 7, 14 and 30 after administration of NT-I7 or placebo compared to baseline values.

Measure: Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.

Time: Up to approximately 30 days


No related HPO nodes (Using clinical trials)